Pharmafile Logo
Pharmafocus logo
Advanced Search

Sanofi

Showing 15 posts of 552 posts found.

Sanofi’s Troujeo beats insulin degludec in head-to-head study in type 2 diabetes

September 19, 2019
Research and Development Sanofi, Troujeo, diabetes, insulin degludec, pharma

Sanofi took the opportunity at the 55th annual European Association for the Study of Diabetes to present new data from …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

August 9, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, CAR T, CAR-T, Eli Lilly, Lexicon, Medicare, Novartis, Pfizer, Sanofi, pharma

This week’s top story covered the scandal surrounding Novartis over its covering up of faulty data from the FDA. The …

News
dupixentpackage

Sanofi’s Dupixent improves skin clearance in paediatric atopic dermatitis

August 7, 2019
Research and Development Dupixent, Sanofi, atopic dermatitis, pharma

As the therapy secured approval in Europe for treatment of adolescent patients with moderate-to-severe atopic dermatitis, Sanofi has revealed new …

News

Sanofi’s Dupixent extended in Europe to cover adolescents in atopic dermatitis

August 6, 2019
Manufacturing and Production, Sales and Marketing EU, Europe, Sanofi, atopic dermatits, pharma

Sanofi has announced that European Commission (EC) has chosen to extend the marketing approval of its interleukin-4 (IL-4) and interleukin-13 …

News

Sanofi ends partnership with Lexicon after release of Phase 3 data

July 29, 2019
Sales and Marketing Lexicon, Sanofi, Zynquista, diabetes, pharma

French firm Sanofi has said it is ending its partnership with Texas-based firm Lexicon Pharmaceuticals over the development of diabetes …

News
shutterstock_158366573

Libtayo becomes first EU-approved therapy for advanced cutaneous squamous cell carcinoma

July 2, 2019
Manufacturing and Production, Sales and Marketing Europe, Libtayo, Regeneron, Sanofi, carcinoma, pharma

The European Commission has revealed that it has decided to award approval, albeit conditionally, to Sanofi and Regeneron’s Libtayo (cemiplimab) …

News
dw-anzcxqaqavhl

FDA approves Dupixent for chronic rhinosinusitis with nasal polyposis

June 27, 2019
Sales and Marketing Dupixent, FDA, Sanofi, US, pharma, rhinosinusitis

Regeneron Pharmaceuticals and Sanofi have revealed that their dual IL-4 and IL-13 inhibitor Dupixent (dupilumab) has secured FDA approval in …

News
shutterstock_114045100

Sanofi to axe 466 R&D positions in Germany and France

June 21, 2019
Medical Communications, Research and Development, Sales and Marketing Sanofi, pharma

Sanofi has announced that plans to reorganise its research and development operations will result in the losses of 466 jobs …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

June 14, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, GSK, J&J, JJ, Otsuka, Pfizer, Purdue, Sanofi, Vertex, pharma

Pfizer supressed research showing their arthritis drug Enbrel reduced the risk of Alzheimer’s. This was the big revelation this week! …

News

Sanofi’s Soliqua proves superior to GLP-1 RA therapies in reducing blood sugar levels

June 10, 2019
Research and Development, Sales and Marketing Sanofi, Soliqua, diabetes, pharma, type 2 diabetes

Sanofi has stepped up at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco, revealing new data which …

News
paul-hudson-big-image

Novartis Pharma head to become new Sanofi CEO

June 7, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, Paul Hudson, Sanofi, appointment, olivier brandicourt, pharma

French drugmaker Sanofi has revealed that its CEO Olivier Brandicourt is to retire from the role, to be replaced with …

News

Isatuximab improves on standard of care treatments for multiple myeloma

June 3, 2019
Sales and Marketing Cancer, Immunogen, Sanofi, isatuximab, multiple myeloma, pharma

Sanofi and ImmunoGen’s isatuximab combination therapy prolonged progression free survival by five months compared to standard of care treatments in …

News
dietmar_berger

Dr Dietmar Berger returns to big pharma

May 31, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Atara, R&D, Sanofi, oncology, pharma, research

Industry veteran Dr Dietmar Berger has joined Sanofi as the company’s new Global Head of Development. Dr Berger joins the …

Appointment
dupixentpackage

Sanofi’s Dupixent approved in Europe for severe asthma maintenance

May 9, 2019
Sales and Marketing Dupixent, EU, Europe, Sanofi, asthma, pharma

Sanofi has revealed that its interleukin-4 and interleukin-13 (IL-4 and IL-13) inhibitor Dupixent (dupilumab) has been awarded marketing approval by …

News

Sanofi’s Dengvaxia becomes first FDA-approved dengue vaccine, but with caveats…

May 2, 2019
Sales and Marketing FDA, Sanofi, dengue, dengvaxia, pharma

Sanofi has announced that the FDA has granted authorisation to its tetravalent vaccine Dengvaxia for prevention of dengue disease originating …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023